Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

Philipp Harter; Andreas Du Bois; Maik Hahmann; Annette Hasenburg; Alexander Burges; Sibylle Loibl; Martina Gropp; Jens Huober; Daniel Fink; Willibald Schröder; Karsten Muenstedt; Barbara Schmalfeldt; Guenter Emons; Jacobus Pfisterer; Kerstin Wollschlaeger; Hans Gerd Meerpohl; Georg Peter Breitbach; Berno Tanner; Jalid Sehouli

doi:10.1245/s10434-006-9058-0

Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

Philipp Harter
, Andreas Du Bois
, Maik Hahmann
, Annette Hasenburg
, Alexander Burges
, Sibylle Loibl
, Martina Gropp
, Jens Huober
, Daniel Fink
, Willibald Schröder
, Karsten Muenstedt
, Barbara Schmalfeldt
, Guenter Emons
, Jacobus Pfisterer
, Kerstin Wollschlaeger
, Hans Gerd Meerpohl
, Georg Peter Breitbach
, Berno Tanner
, Jalid Sehouli

Dr. Horst-Schmidt-Klinik
Philipps-Universität Marburg
Albert-Ludwigs-Universität Freiburg
Ludwig-Maximilians-Universität München
Johann Wolfgang Goethe University
EVK Duesseldorf
Universitätsklinikum Tübingen
University of Zurich
Central Hospital
Justus-Liebig-Universität Gießen
Georg-August-Universität Göttingen
University Hospital Schleswig-Holstein
Otto-von-Guericke University
Formerly St.-Vincentius-Hospital
City Hospital Neunkirchen
Johannes Gutenberg University
Charité – Universitätsmedizin Berlin

Research output: Contribution to journal › Article › peer-review

414 Scopus citations

Abstract

Background: The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's preference rather than on established selection criteria. The Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian cancer (DESKTOP OVAR) trial was undertaken to form a hypothesis for a panel of criteria for selecting patients who might benefit from surgery in relapsed ovarian cancer. Methods: The DESKTOP trial was an exploratory study based on data from a retrospective analysis of hospital records. Twenty-five member institutions of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and AGO-OVAR boards collected data on their patients with cytoreductive surgery for relapsed invasive epithelial ovarian cancer performed in 2000-2003. Results: Two hundred and sixty-seven patients were included. Complete resection was associated with significantly longer survival compared with surgery leaving any postoperative residuals [median 45.2 vs. 19.7 months; hazard ratio (HR) 3.71; 95% confidence interval (CI) 2.27-6.05; P < .0001]. Variables associated with complete resection were performance status (PS) [Eastern Cooperative Oncology Group (ECOG) 0 vs. > 0; P < .001], International Federation of Gynecology and Obstetrics (FIGO) stage at initial diagnosis (FIGO I/II vs. III/IV, P = .036), residual tumor after primary surgery (none vs. present, P <.001), and absence of ascites > 500 ml (P < .001). A combination of PS, early FIGO stage initially or no residual tumor after first surgery, and absence of ascites could predict complete resection in 79% of patients. Conclusions: Only complete resection was associated with prolonged survival in recurrent ovarian cancer. The identified criteria panel will be verified in a prospective trial (AGO-DESKTOP II) evaluating whether it will render a useful tool for selecting the right patients for cytoreductive surgery in recurrent ovarian cancer.

Original language	English
Pages (from-to)	1702-1710
Number of pages	9
Journal	Annals of Surgical Oncology
Volume	13
Issue number	12
DOIs	https://doi.org/10.1245/s10434-006-9058-0
State	Published - Dec 2006
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Ovarian cancer
Ovarian neoplasm
Recurrence
Secondary cytoreductive surgery

Access to Document

10.1245/s10434-006-9058-0

Cite this

Harter, P., Bois, A. D., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., Schröder, W., Muenstedt, K., Schmalfeldt, B., Emons, G., Pfisterer, J., Wollschlaeger, K., Meerpohl, H. G., Breitbach, G. P., Tanner, B., & Sehouli, J. (2006). Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of Surgical Oncology, 13(12), 1702-1710. https://doi.org/10.1245/s10434-006-9058-0

@article{8f643f4ba4fe4e0abdb3320982f02f08,

title = "Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial",

abstract = "Background: The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's preference rather than on established selection criteria. The Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian cancer (DESKTOP OVAR) trial was undertaken to form a hypothesis for a panel of criteria for selecting patients who might benefit from surgery in relapsed ovarian cancer. Methods: The DESKTOP trial was an exploratory study based on data from a retrospective analysis of hospital records. Twenty-five member institutions of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and AGO-OVAR boards collected data on their patients with cytoreductive surgery for relapsed invasive epithelial ovarian cancer performed in 2000-2003. Results: Two hundred and sixty-seven patients were included. Complete resection was associated with significantly longer survival compared with surgery leaving any postoperative residuals [median 45.2 vs. 19.7 months; hazard ratio (HR) 3.71; 95\% confidence interval (CI) 2.27-6.05; P < .0001]. Variables associated with complete resection were performance status (PS) [Eastern Cooperative Oncology Group (ECOG) 0 vs. > 0; P < .001], International Federation of Gynecology and Obstetrics (FIGO) stage at initial diagnosis (FIGO I/II vs. III/IV, P = .036), residual tumor after primary surgery (none vs. present, P <.001), and absence of ascites > 500 ml (P < .001). A combination of PS, early FIGO stage initially or no residual tumor after first surgery, and absence of ascites could predict complete resection in 79\% of patients. Conclusions: Only complete resection was associated with prolonged survival in recurrent ovarian cancer. The identified criteria panel will be verified in a prospective trial (AGO-DESKTOP II) evaluating whether it will render a useful tool for selecting the right patients for cytoreductive surgery in recurrent ovarian cancer.",

keywords = "Ovarian cancer, Ovarian neoplasm, Recurrence, Secondary cytoreductive surgery",

author = "Philipp Harter and Bois, \{Andreas Du\} and Maik Hahmann and Annette Hasenburg and Alexander Burges and Sibylle Loibl and Martina Gropp and Jens Huober and Daniel Fink and Willibald Schr{\"o}der and Karsten Muenstedt and Barbara Schmalfeldt and Guenter Emons and Jacobus Pfisterer and Kerstin Wollschlaeger and Meerpohl, \{Hans Gerd\} and Breitbach, \{Georg Peter\} and Berno Tanner and Jalid Sehouli",

year = "2006",

month = dec,

doi = "10.1245/s10434-006-9058-0",

language = "English",

volume = "13",

pages = "1702--1710",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "12",

}

Harter, P, Bois, AD, Hahmann, M, Hasenburg, A, Burges, A, Loibl, S, Gropp, M, Huober, J, Fink, D, Schröder, W, Muenstedt, K, Schmalfeldt, B, Emons, G, Pfisterer, J, Wollschlaeger, K, Meerpohl, HG, Breitbach, GP, Tanner, B & Sehouli, J 2006, 'Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial', Annals of Surgical Oncology, vol. 13, no. 12, pp. 1702-1710. https://doi.org/10.1245/s10434-006-9058-0

TY - JOUR

T1 - Surgery in recurrent ovarian cancer

T2 - The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

AU - Harter, Philipp

AU - Bois, Andreas Du

AU - Hahmann, Maik

AU - Hasenburg, Annette

AU - Burges, Alexander

AU - Loibl, Sibylle

AU - Gropp, Martina

AU - Huober, Jens

AU - Fink, Daniel

AU - Schröder, Willibald

AU - Muenstedt, Karsten

AU - Schmalfeldt, Barbara

AU - Emons, Guenter

AU - Pfisterer, Jacobus

AU - Wollschlaeger, Kerstin

AU - Meerpohl, Hans Gerd

AU - Breitbach, Georg Peter

AU - Tanner, Berno

AU - Sehouli, Jalid

PY - 2006/12

Y1 - 2006/12

N2 - Background: The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's preference rather than on established selection criteria. The Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian cancer (DESKTOP OVAR) trial was undertaken to form a hypothesis for a panel of criteria for selecting patients who might benefit from surgery in relapsed ovarian cancer. Methods: The DESKTOP trial was an exploratory study based on data from a retrospective analysis of hospital records. Twenty-five member institutions of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and AGO-OVAR boards collected data on their patients with cytoreductive surgery for relapsed invasive epithelial ovarian cancer performed in 2000-2003. Results: Two hundred and sixty-seven patients were included. Complete resection was associated with significantly longer survival compared with surgery leaving any postoperative residuals [median 45.2 vs. 19.7 months; hazard ratio (HR) 3.71; 95% confidence interval (CI) 2.27-6.05; P < .0001]. Variables associated with complete resection were performance status (PS) [Eastern Cooperative Oncology Group (ECOG) 0 vs. > 0; P < .001], International Federation of Gynecology and Obstetrics (FIGO) stage at initial diagnosis (FIGO I/II vs. III/IV, P = .036), residual tumor after primary surgery (none vs. present, P <.001), and absence of ascites > 500 ml (P < .001). A combination of PS, early FIGO stage initially or no residual tumor after first surgery, and absence of ascites could predict complete resection in 79% of patients. Conclusions: Only complete resection was associated with prolonged survival in recurrent ovarian cancer. The identified criteria panel will be verified in a prospective trial (AGO-DESKTOP II) evaluating whether it will render a useful tool for selecting the right patients for cytoreductive surgery in recurrent ovarian cancer.

AB - Background: The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's preference rather than on established selection criteria. The Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian cancer (DESKTOP OVAR) trial was undertaken to form a hypothesis for a panel of criteria for selecting patients who might benefit from surgery in relapsed ovarian cancer. Methods: The DESKTOP trial was an exploratory study based on data from a retrospective analysis of hospital records. Twenty-five member institutions of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and AGO-OVAR boards collected data on their patients with cytoreductive surgery for relapsed invasive epithelial ovarian cancer performed in 2000-2003. Results: Two hundred and sixty-seven patients were included. Complete resection was associated with significantly longer survival compared with surgery leaving any postoperative residuals [median 45.2 vs. 19.7 months; hazard ratio (HR) 3.71; 95% confidence interval (CI) 2.27-6.05; P < .0001]. Variables associated with complete resection were performance status (PS) [Eastern Cooperative Oncology Group (ECOG) 0 vs. > 0; P < .001], International Federation of Gynecology and Obstetrics (FIGO) stage at initial diagnosis (FIGO I/II vs. III/IV, P = .036), residual tumor after primary surgery (none vs. present, P <.001), and absence of ascites > 500 ml (P < .001). A combination of PS, early FIGO stage initially or no residual tumor after first surgery, and absence of ascites could predict complete resection in 79% of patients. Conclusions: Only complete resection was associated with prolonged survival in recurrent ovarian cancer. The identified criteria panel will be verified in a prospective trial (AGO-DESKTOP II) evaluating whether it will render a useful tool for selecting the right patients for cytoreductive surgery in recurrent ovarian cancer.

KW - Ovarian cancer

KW - Ovarian neoplasm

KW - Recurrence

KW - Secondary cytoreductive surgery

UR - https://www.scopus.com/pages/publications/33845657404

U2 - 10.1245/s10434-006-9058-0

DO - 10.1245/s10434-006-9058-0

M3 - Article

C2 - 17009163

AN - SCOPUS:33845657404

SN - 1068-9265

VL - 13

SP - 1702

EP - 1710

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

IS - 12

ER -

Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this